Pfizer invests $500K in decentralized collective focused on longevity R&D

Pfizer signaled its interest in longevity research through a new partnership -and a $500,000 investment – in a decentralized drug development program driven by VitaDAO, a cooperative focused on developing therapeutics to extend human life.